Cytochrome P450 1A2
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytochrome P450 1A2 as ChEMBL target CHEMBL3356, mapped to UniProt P05177. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Cytochrome P450 1A2 matters
Cytochrome P450 1A2 is reviewed as Cytochrome P450 1A2 (UniProt P05177); the current evidence base includes 47 approved drugs, 24030 compounds, and 2453 assays, with lead potency reaching pChEMBL 9.9.
Cytochrome P450 1A2 Sequence length is 516 aa.
Review this target as Cytochrome P450 1A2, mapped to UniProt P05177. Sequence length is 516 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 47 approved drugs, 24030 compounds, and 2453 assays for this target. The dominant activity type is IC50. CHEMBL5279681 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL5279681 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Cytochrome P450 1A2 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P05177, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5279681
|
9.9 | IC50 | — |
|
|
No preferred name
CHEMBL4447260
|
8.8 | IC50 | — |
|
|
No preferred name
CHEMBL283196
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL1223034
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL4456952
|
8.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ALOSETRON
CHEMBL1110
|
2000 |
|
|
LEFLUNOMIDE
CHEMBL960
|
1998 |
|
|
NISOLDIPINE
CHEMBL1726
|
1995 |
|
|
SULCONAZOLE
CHEMBL1221
|
1985 |
|
|
ECONAZOLE
CHEMBL808
|
1982 |
|
|
TANNIC ACID
CHEMBL506247
|
1982 |
|
|
NIFEDIPINE
CHEMBL193
|
1981 |
|
|
THIABENDAZOLE
CHEMBL625
|
1967 |
|
|
METHOXSALEN
CHEMBL416
|
1954 |
|
|
PRIMAQUINE
CHEMBL506
|
1952 |
|
|
PHENACETIN
CHEMBL16073
|
— |